Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of a Single Oral Dose of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI

NCT02157883 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02157883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02157883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of a Single Oral Dose of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
November 6, 2014
Completion date
May 17, 2023
Enrollment
39 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced (inoperable) non small cell lung cancer, advanced non small cell lung cancer